Price
CHART BY
Frequently asked questions
What is Formycon's market capitalization?
The market capitalization of Formycon is $396.30M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Formycon?
Formycon's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.654. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Formycon's stock?
Currently, 6 analysts cover Formycon's stock, with a consensus target price of $47.69. Analyst ratings provide insights into the stock's expected performance.
What is Formycon's revenue over the trailing twelve months?
Over the trailing twelve months, Formycon reported a revenue of $71.23M.
What is the EBITDA for Formycon?
Formycon's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $11.87M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Formycon?
Formycon has a free cash flow of -$6.54M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Formycon have, and what sector and industry does it belong to?
Formycon employs approximately 203 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Formycon's shares?
The free float of Formycon is 8.00M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $396.30M
- EPS (TTM)
- -$1.654
- Free Float
- 8.00M
- Revenue (TTM)
- $71.23M
- EBITDA (TTM)
- $11.87M
- Free Cashflow (TTM)
- -$6.54M
Pricing
- 1D span
- $22.26$24.20
- 52W span
- $18.35$31.58
Analyst Ratings
The price target is $47.69 and the stock is covered by 6 analysts.
Buy
6
Hold
0
Sell
0
Information
Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205, which focuses in the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.
- Employees
- 203
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- DE000A1EWVY8
- Primary Ticker
- FYB
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet